Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes

A fibrinolytic agent consisting of a tissue-type plasminogen activator (tPA) coupled to the surface of red blood cells (RBCs) can dissolve nascent clots from within the clot, in a Trojan horse–like strategy, while having minimal effects on preexisting hemostatic clots or extravascular tissue. After intravenous injection, the fibrinolytic activity of RBC-tPA persisted in the bloodstream at least tenfold longer than did that of free tPA. In a model of venous thrombosis induced by intravenously injected fibrin microemboli aggregating in pulmonary vasculature, soluble tPA lysed pulmonary clots lodged before but not after tPA injection, whereas the converse was true for RBC-tPA. Free tPA failed to lyse occlusive carotid thrombosis whether injected before or after vascular trauma, whereas RBC-tPA circulating before, but not injected after, thrombus formation restored blood flow. This RBC-based drug delivery strategy alters the fibrinolytic profile of tPA, permitting prophylactic fibrinolysis.

[1]  E. Beutler,et al.  Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[2]  V. Muzykantov,et al.  Targeting of antibody-conjugated plasminogen activators to the pulmonary vasculature. , 1996, The Journal of pharmacology and experimental therapeutics.

[3]  J. Gurwitz,et al.  Risk for Intracranial Hemorrhage after Tissue Plasminogen Activator Treatment for Acute Myocardial Infarction , 1998, Annals of Internal Medicine.

[4]  J W Eaton,et al.  Chemical camouflage of antigenic determinants: stealth erythrocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Califf,et al.  Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. , 1995, Circulation.

[6]  V. Muzykantov,et al.  Avidin attachment to biotinylated erythrocytes induces homologous lysis via the alternative pathway of complement. , 1991, Blood.

[7]  F. Fazio,et al.  Two-step tumour targetting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin , 2004, European Journal of Nuclear Medicine.

[8]  M. Magnani,et al.  Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Heit,et al.  Prevention of venous thromboembolism. , 2001, Clinics in geriatric medicine.

[10]  V. Muzykantov,et al.  Platelets inhibit the lysis of pulmonary microemboli. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[11]  E. L. Wright,et al.  Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Houng,et al.  A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R H Glew,et al.  Enzyme loading of erythrocytes. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Dewerchin,et al.  Thrombolytic Profiles of Clot‐Targeted Plasminogen Activators Parameters Determining Potency and Initial and Maximal Rates , 1993, Circulation.

[15]  V R Muzykantov,et al.  Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor. , 1995, The Biochemical journal.

[16]  T. Hoy,et al.  The measurement of the total volume of red cells in man: a non‐radioactive approach using biotin , 1988, British journal of haematology.

[17]  H. Meiselman,et al.  Polyethylene glycol-coated red blood cells fail to bind glycophorin A-specific antibodies and are impervious to invasion by the Plasmodium falciparum malaria parasite. , 2001, Blood.

[18]  R. Keep,et al.  Plasminogen activators potentiate thrombin-induced brain injury. , 1998, Stroke.

[19]  B. Keyt,et al.  New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. , 1995, Circulation.

[20]  Microemboli in cerebral circulation and alteration of cognitive abilities in patients with mechanical prosthetic heart valves. , 1999, Stroke.

[21]  D. Birmingham,et al.  Primate erythrocyte-immune complex-clearing mechanism. , 1983, The Journal of clinical investigation.

[22]  V. Muzykantov,et al.  Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin. , 1996, Analytical biochemistry.

[23]  P. Carmeliet,et al.  Physiological consequences of loss of plasminogen activator gene function in mice , 1994, Nature.

[24]  J. Hoak,et al.  Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. , 1996, Circulation.

[25]  B. Keyt,et al.  Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. , 1999, Journal of cell science.

[26]  F. Davis,et al.  Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.

[27]  S. Strickland,et al.  Neuronal Death in the Hippocampus Is Promoted by Plasmin-Catalyzed Degradation of Laminin , 1997, Cell.

[28]  P. Carmeliet,et al.  Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. , 1998, Circulation.

[29]  M. Magnani,et al.  Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides , 2002, Gene Therapy.

[30]  Sidney Strickland,et al.  Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator , 1995, Nature.

[31]  B. Bax,et al.  In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol‐conjugated and native adenosine deaminase , 2000, British journal of haematology.

[32]  Joseph P. Broderick,et al.  Effects of tissue plasminogen activator for acute ischemic stroke at one year , 1999 .

[33]  V. Muzykantov,et al.  Carrier-directed targeting of liposomes and erythrocytes to denuded areas of vessel wall. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Schwartz,et al.  Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Crommelin,et al.  Thrombolytic Treatment with Tissue-type Plasminogen Activator (t-PA) Containing Liposomes in Rabbits: a Comparison with Free t-PA , 1995, Thrombosis and Haemostasis.

[36]  H. Kalofonos,et al.  Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  S. Diamond,et al.  Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction. , 1996, Circulation.

[38]  P. Carmeliet,et al.  Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. , 1999, Circulation.

[39]  T. Speroff,et al.  A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. , 1994, JAMA.

[40]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[41]  L Bigi,et al.  Erythrocyte‐mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease , 2001, Biotechnology and applied biochemistry.

[42]  D. Collen.  Fibrin-selective thrombolytic therapy for acute myocardial infarction. , 1996, Circulation.

[43]  V. Muzykantov,et al.  Urokinase mediates fibrinolysis in the pulmonary microvasculature. , 2000, Blood.

[44]  V R Muzykantov,et al.  Attachment of biotinylated antibody to red blood cells: antigen-binding capacity of immunoerythrocytes and their susceptibility to lysis by complement. , 1994, Analytical biochemistry.

[45]  M. Magnani,et al.  Red blood cells as an antigen‐delivery system , 1992, Biotechnology and applied biochemistry.

[46]  J. Broderick,et al.  Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. , 1999, The New England journal of medicine.

[47]  J. Hammon,et al.  Longer duration of cardiopulmonary bypass is associated with greater numbers of cerebral microemboli. , 2000, Stroke.

[48]  E. Haber,et al.  Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. , 1996, Circulation.

[49]  D. Rijken,et al.  Superficial accumulation of plasminogen during plasma clot lysis. , 1995, Circulation.

[50]  S. Lipton,et al.  Tissue plasminogen activator (tPA) increase neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice , 1998, Nature Medicine.

[51]  C. Colwell,et al.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.